S-1226 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
299Cystic fibrosis1

299. Cystic fibrosis


Clinical trials : 1,695 Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03903913
(ClinicalTrials.gov)
August 8, 201915/2/2019Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF BronchiectasisA Phase IIa Open Label Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 Administered by Nebulization in Subjects With Mild to Moderate Cystic Fibrosis and Non CF BronchiectasisCystic Fibrosis;BronchiectasisDrug: S-1226SolAeroMed Inc.NULLRecruiting14 Years50 YearsAll12Phase 2Canada